Which are the best Chinese herbal injections combined with XELOX regimen for gastric cancer?: A PRISMA-compliant network meta-analysis.

Dan Zhang, Jiarui Wu, Kaihuan Wang, Xiaojiao Duan, Shi Liu, Bing Zhang
Author Information
  1. Dan Zhang: Department of Clinical Chinese Pharmacy, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.

Abstract

BACKGROUND: The optimal Chinese herbal injections (CHIs) combined with XELOX regimen for patients with gastric cancer remains elusive. The aim of our network meta-analysis (NMA) is to explore the best options among different CHIs for gastric cancer.
METHODS: PubMed, Embase, the Cochrane Library, the China National Knowledge Infrastructure Database (CNKI), Wan-fang Database, Cqvip Database (VIP), China Biology Medicine disc (CBMdisc) were searched to identify RCTs which focused on CHIs against gastric cancer. The quality assessment of included randomized controlled trials (RCTs) was conducted by the Cochrane risk of bias tool. Standard pair-wise and Bayesian NMAs were performed to compare the efficacy and safety of different CHIs combined with the XELOX regimen via Stata 13.0 and WinBUGS1.4 software.
RESULTS: A total of 2316 records were searched, the network of evidence included 26 eligible RCTs involving 13 types of CHIs and 2154 patients. The results suggested that Shenqifuzheng+ XELOX, Huachansu+ XELOX, Kangai+ XELOX, Javanica oil emulsion+ XELOX, Aidi injection+ XELOX might be the optimal treatment for gastric cancer in improving the performance status than using XELOX regimen single, with odds ratios (OR) and 95% confidence intervals (CIs) of 2.74 (1.24, 6.17), 8.27 (1.74, 42.43), 4.28 (1.80, 10.48), 5.14 (1.87, 16.28), 0.20 (0.090, 0.44). At the aspects of ADRs (adverse reactions), Compound Kushen+ XELOX, Lentinan+ XELOX, Xiaoaiping injection+ XELOX could obviously relieve leukopenia than only receiving XELOX regimen, and their ORs and 95% CIs were 5.62 (1.41, 36.24), 8.16 (2.25, 29.43), 5.69 (1.85, 15.77). Furthermore, Disodium cantharidinate and vitamin B6+ XELOX, Shenqifuzheng+ XELOX, Kangai+ XELOX, Lentinan+ XELOX could obviously relieve the nausea and vomiting than receiving the XELOX regimen alone, with ORs and 95% CIs of 5.29 (1.30, 23.96), 2.50 (1.16, 5.26), 2.42 (1.06, 5.63), 9.04 (3.24, 26.73). Nevertheless, CHIs combined with XELOX regimen did not confer higher better clinical effectiveness rate over receiving XELOX regimen alone, with nonstatistically significant between-group differences.
CONCLUSIONS: As the available evidence suggested that CHIs combined with XELOX regimen could provide treatment benefits for patients with gastric cancer. Among 13 types of CHIs, Javanica oil emulsion and Compound Kushen injection is the optimal treatment in improving the clinical effectiveness rate and performance status, and Lentinan injection was superior in relieving ADRs.

References

  1. J Clin Epidemiol. 2009 Aug;62(8):857-64 [PMID: 19157778]
  2. J Gastroenterol Hepatol. 2010 Mar;25(3):479-86 [PMID: 20370726]
  3. Curr Opin Clin Nutr Metab Care. 2010 Nov;13(6):656-61 [PMID: 20842027]
  4. Biosci Trends. 2010 Dec;4(6):297-307 [PMID: 21248427]
  5. Chin J Integr Med. 2011 Jan;17(1):64-70 [PMID: 21258899]
  6. Stat Med. 2011 Sep 10;30(20):2481-98 [PMID: 21268052]
  7. Ann Oncol. 2011 Oct;22(10):2241-9 [PMID: 21355071]
  8. J Stat Softw. 2010 Jan 1;32(11):null [PMID: 21743798]
  9. J Toxicol Sci. 2011 Aug;36(4):411-22 [PMID: 21804305]
  10. Oncologist. 2012;17(1):15-25 [PMID: 22234633]
  11. Pathol Oncol Res. 2012 Jul;18(3):697-702 [PMID: 22246794]
  12. Stat Methods Med Res. 2013 Apr;22(2):133-58 [PMID: 22275379]
  13. Semin Oncol Nurs. 2012 Feb;28(1):64-74 [PMID: 22281311]
  14. Asian Pac J Cancer Prev. 2011;12(9):2233-6 [PMID: 22296362]
  15. Zhongguo Zhong Yao Za Zhi. 2011 Nov;36(22):3207-9 [PMID: 22375409]
  16. Br J Cancer. 2012 Jul 24;107(3):405 [PMID: 22828654]
  17. Anticancer Agents Med Chem. 2013 Jun;13(5):681-8 [PMID: 23092289]
  18. J Tradit Chin Med. 2012 Sep;32(3):299-307 [PMID: 23297547]
  19. Diagn Pathol. 2013 Jun 21;8:102 [PMID: 23786758]
  20. BMC Med. 2013 Jul 04;11:159 [PMID: 23826681]
  21. Stat Methods Med Res. 2016 Oct;25(5):1757-1773 [PMID: 23970014]
  22. J Cancer Educ. 2014 Mar;29(1):56-61 [PMID: 24072455]
  23. PLoS One. 2013 Oct 03;8(10):e76654 [PMID: 24098547]
  24. Int Heart J. 2013;54(6):417-20 [PMID: 24309454]
  25. World J Gastroenterol. 2014 Feb 21;20(7):1635-49 [PMID: 24587643]
  26. Asian Pac J Cancer Prev. 2014;15(3):1241-5 [PMID: 24606447]
  27. World J Gastroenterol. 2014 Apr 28;20(16):4483-90 [PMID: 24782601]
  28. Am J Chin Med. 2014;42(3):543-59 [PMID: 24871650]
  29. World J Gastroenterol. 2014 May 28;20(20):6092-101 [PMID: 24876731]
  30. PLoS One. 2014 Oct 06;9(10):e109814 [PMID: 25286158]
  31. World J Gastroenterol. 2014 Oct 14;20(38):13667-80 [PMID: 25320505]
  32. World J Gastroenterol. 2014 Oct 14;20(38):13767-74 [PMID: 25320514]
  33. BMC Complement Altern Med. 2014 Dec 13;14:483 [PMID: 25496480]
  34. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2014 Sep;30(5):417-20 [PMID: 25571632]
  35. CA Cancer J Clin. 2015 Mar;65(2):87-108 [PMID: 25651787]
  36. Biosci Trends. 2015 Feb;9(1):16-34 [PMID: 25787906]
  37. Eur J Clin Pharmacol. 2015 May;71(5):589-601 [PMID: 25795200]
  38. Acta Pharmacol Sin. 2015 Jun;36(6):676-9 [PMID: 25982630]
  39. BMC Med Res Methodol. 2015 Jul 31;15:58 [PMID: 26227148]
  40. J Tradit Chin Med. 2015 Aug;35(4):361-74 [PMID: 26427104]
  41. J Pharmacol Sci. 2016 Apr;130(4):189-93 [PMID: 26790975]
  42. CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32 [PMID: 26808342]
  43. PLoS Negl Trop Dis. 2016 Feb 05;10(2):e0004418 [PMID: 26849048]
  44. Medicine (Baltimore). 2016 Mar;95(9):e3004 [PMID: 26945424]
  45. Int J Mol Sci. 2016 Mar 22;17(3):424 [PMID: 27011182]
  46. Oncotarget. 2016 May 24;7(21):30642-58 [PMID: 27121321]
  47. JAMA. 2016 Jun 14;315(22):2424-34 [PMID: 27299618]
  48. J Natl Compr Canc Netw. 2016 Oct;14(10):1286-1312 [PMID: 27697982]
  49. Medicine (Baltimore). 2016 Dec;95(49):e5490 [PMID: 27930534]
  50. PLoS One. 2017 Jan 12;12(1):e0169141 [PMID: 28081155]
  51. BMJ. 1997 Sep 13;315(7109):629-34 [PMID: 9310563]

MeSH Term

Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Capecitabine
Deoxycytidine
Drugs, Chinese Herbal
Fluorouracil
Humans
Network Meta-Analysis
Oxaloacetates
Stomach Neoplasms

Chemicals

Antineoplastic Agents
Drugs, Chinese Herbal
Oxaloacetates
Deoxycytidine
Capecitabine
Fluorouracil

Word Cloud

Created with Highcharts 10.0.0XELOXregimen1CHIsgastric5combinedcancer02optimalpatientsnetworkDatabaseRCTs1326treatment95%CIs2416receivingChineseherbalinjectionsmeta-analysisbestdifferentCochraneChinasearchedincluded4evidencetypessuggestedShenqifuzheng+Kangai+Javanicaoilinjection+improvingperformancestatus748424328ADRsCompoundLentinan+obviouslyrelieveORs29aloneclinicaleffectivenessrateinjectionBACKGROUND:remainselusiveaimNMAexploreoptionsamongMETHODS:PubMedEmbaseLibraryNationalKnowledgeInfrastructureCNKIWan-fangCqvipVIPBiologyMedicinediscCBMdiscidentifyfocusedqualityassessmentrandomizedcontrolledtrialsconductedriskbiastoolStandardpair-wiseBayesianNMAsperformedcompareefficacysafetyviaStataWinBUGS1softwareRESULTS:total2316recordseligibleinvolving2154resultsHuachansu+emulsion+AidimightusingsingleoddsratiosORconfidenceintervals6172780104814872009044aspectsadversereactionsKushen+Xiaoaipingleukopenia6241362569851577FurthermoreDisodiumcantharidinatevitaminB6+nauseavomiting302396500663904373Neverthelessconferhigherbetternonstatisticallysignificantbetween-groupdifferencesCONCLUSIONS:availableprovidebenefitsAmongemulsionKushenLentinansuperiorrelievingcancer?:PRISMA-compliant

Similar Articles

Cited By